A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study

Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia

(2013) Rebecca B. Klisovic et al.   LEUKEMIA & LYMPHOMA

Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2

(2010) Eckhardt S. Ferdinandi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer

(2010) Srikala S. Sridhar et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium

(2010) Natasha B. Leighl et al.   Journal of Thoracic Oncology

Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study

(2009) Stephen I. Shibata et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia

(2008) R. B. Klisovic et al.   CLINICAL CANCER RESEARCH